Endothelin-1

FDA grants full approval to Filspari, a daily oral, non-immunosuppressive medication, to slow kidney function decline in adults with primary IgA nephropathy. The approval is based on the phase 3 PROTECT study, which showed that Filspari significantly slowed kidney function decline compared to irbesartan.

FDA grants full approval to FILSPARI (sparsentan) for IgA nephropathy (IgAN), based on PROTECT Study results showing superior kidney function preservation over irbesartan. FILSPARI is an oral, non-immunosuppressive, once-daily treatment targeting glomerular injury, with a durable benefit on proteinuria and kidney function over two years.

FDA grants full approval to FILSPARI for IgA nephropathy, based on PROTECT Study results showing superior kidney function preservation over irbesartan. FILSPARI, an oral, non-immunosuppressive treatment, targets glomerular injury and reduces proteinuria, positioning it as foundational care for IgAN.

Travere Therapeutics announces FDA full approval of Filspari (sparsentan) to slow kidney function decline in IgA nephropathy, based on PROTECT Study results showing significant benefit over irbesartan.

Landiolol, an ultrashort-acting beta1-selective beta-blocker, effectively controls heart rate in ICU patients with atrial fibrillation, including those with sepsis, without significant hypotension. Studies show it safely reduces heart rate, with many patients converting to sinus rhythm. Its use in septic shock patients without Afib for potential benefits like inflammation attenuation requires further research.